Prognostic Value of Monoclonal Antibodies in Breast Cancer
Author Information
Author(s): N. Berry, D.B. Jones, J. Smallwood, I. Taylor, N. Kirkham, J. Taylor-Papadimitriou
Primary Institution: University of Southampton
Hypothesis
Do the monoclonal antibodies HMFG1 and HMFG2 provide prognostic information in breast cancer?
Conclusion
The study found that the staining patterns of HMFG1 and HMFG2 do not assist in determining prognosis in breast carcinoma.
Supporting Evidence
- Immunohistochemical staining patterns were characterized and graded in malignant breast tissue.
- No correlation was found between staining grades and survival or indices of prognosis.
- 84% reproducibility of staining grades was achieved on separate occasions.
Takeaway
This study looked at how certain antibodies behave in breast cancer tissues, and it turns out they don't really help doctors predict how a patient will do.
Methodology
Immunohistochemical staining was performed on tissue sections from 130 women with breast disease, and staining patterns were graded and correlated with prognostic indicators.
Limitations
The heterogeneity of staining patterns made grading difficult and may have influenced survival outcomes.
Participant Demographics
130 women undergoing surgery for breast disease, with 93 diagnosed with carcinoma and 36 with benign lesions.
Want to read the original?
Access the complete publication on the publisher's website